Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line

Table 1 Clinicopathological characteristics of 114 patients with PDAC

		number
Sex	men	58
Sex	women	56
Age, median (range)		70 (34–85)
Differentiated	differentiated	91
	undifferentiated	16
	other	7
Location of cancer	Head	68
Location of cancer	Body/head	46
T category	pT1	6
	pT2	23
	pT3	82
	pT4	3
Lymph node metastasis	absent	54
Lymph node metastasis	present	60
Distant metastasis	absent	106
Distant metastasis	present	8
Lymphatic invasion	absent	16
Lymphatic invasion	present	98
Vascular invasion	absent	67
Vascular invasion	present	47
Neural invasion	absent	18
Neural invasion	present	96
UICC stage	1	17
	2	86
	3	3
	4	8
Serum CEA level, ng/ml, median (range)		3.6 (0.5–262)
Serum CA19–9 level, U/ml, median (range)		98 (0–10,148)
Serum SPan-1 level, U/ml, median (range)		52 (1–2411)
Recurrence	yes	80
Recurrence	no	34
Outcome	death	75
Outcome	alive	39
Recurrence free survival, days, median (range)		289 (0–5257)
Overall survival, days, median (range)		632 (26–1815)

PDAC pancreatic ductal adenocarcinoma, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, SPan-1 s-pancreas-1 antigen

ISSN: 1471-2407